Form 4: VolitionRx Director Kim Nguyen Receives RSU Award

VolitionRx Director Kim Nguyen was awarded 17,424 restricted stock units in lieu of cash compensation, aligning her interests with shareholders.

Summary

• Director Kim Nguyen was awarded 17,424 restricted stock units (RSUs) under VolitionRx's 2015 Stock Incentive Plan.
• The RSUs were granted on August 15, 2025, in lieu of cash compensation that would otherwise have been owed.
• RSUs will be earned in six approximately equal monthly installments commencing on August 1, 2025.
• Vesting occurs in two equal installments of 8,712 units on November 1, 2025, and February 1, 2026, respectively.
• Vesting is generally subject to continued service by the reporting person throughout each applicable earning and vesting date.
• Upon vesting and settlement, the director will receive a number of shares of common stock equal to the number of vested RSUs.
• Following this transaction, Kim Nguyen directly owns 115,816 shares of common stock and indirectly owns 30,556 shares through her spouse.

Sentiment

Score: 7

Explanation: The award of RSUs to a director is a positive sign of continued commitment and alignment of interests with shareholders, though it is a routine compensation event and not indicative of extraordinary operational performance.

Positives

• Aligns Director Kim Nguyen's interests with those of shareholders through equity-based compensation.
• Demonstrates continued commitment of a key director to the company's long-term performance.
• Utilizes the existing 2015 Stock Incentive Plan, indicating a structured approach to executive and director compensation.

Negatives

• No immediate cash compensation for the director, as RSUs were granted in lieu of cash.
• Potential for minor future dilution upon conversion of RSUs to common stock, though this is standard for equity compensation.

Risks

• The value of the RSUs is subject to the future market price of VolitionRx common stock.
• Vesting is contingent on continued service, meaning the director must remain with the company to fully realize the award.

Future Outlook

The award of restricted stock units to Director Kim Nguyen signifies a continued strategy of aligning management and director incentives with long-term shareholder value through equity compensation. The future value of this compensation is directly tied to the company's stock performance.

Industry Context

The use of restricted stock units (RSUs) as a form of non-cash compensation for directors is a common practice across various industries, particularly in publicly traded companies. It serves to conserve cash while incentivizing long-term performance and retention by linking compensation directly to the company's stock price.

Comparison to Industry Standards

• The practice of awarding equity, such as RSUs, in lieu of cash compensation for directors is a widely adopted standard among public companies, including those in the biotechnology and diagnostic sectors where VolitionRx operates.
• Companies like Exact Sciences Corp. (EXAS) or Guardant Health, Inc. (GH) often utilize similar equity-based compensation structures for their non-employee directors to align their interests with shareholders.
• The vesting schedule, with installments over several months, is also typical, designed to encourage continued service and long-term commitment, comparable to plans seen at peers.

Stakeholder Impact

• Shareholders benefit from increased alignment of the director's financial interests with the company's long-term stock performance.
• Employees: No direct impact mentioned, but consistent equity compensation practices can contribute to overall company culture and retention strategies.

Next Steps

• Continued service by Director Kim Nguyen to meet vesting conditions.
• Vesting of 8,712 RSUs on November 1, 2025.
• Vesting of 8,712 RSUs on February 1, 2026.
• Settlement of vested RSUs into common stock.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation award to a director. While it indicates continued alignment of interests, it does not present new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard disclosure for insider transactions.

Keywords

VolitionRx, VNRX, Restricted Stock Units, RSU, Director Compensation, Equity Award, Insider Transaction, Form 4, Stock Incentive Plan